Abstract
Choline has important physiological functions as a precursor for essential cell components and signaling molecules including phospholipids and the neurotransmitter acetylcholine. Choline is a water-soluble charged molecule and therefore requires transport proteins to cross biological membranes. Membrane transport of choline is incompletely understood. Here we show that SLC25A48 is a human mitochondrial choline transporter. Loss-of-function mutations in SLC25A48 are associated with elevated urine and plasma choline levels resulting from impaired choline transport into mitochondria.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The work of N.S., C.H., B.N., A.K. and M.K. was funded by German Research Foundation (DFG) project ID 431984000 (SFB 1453). N.S. was supported by DFG KO 3598/4-2 (to A.K.). M.K. was supported by German Research Foundation (DFG) project ID 239283807 (TRR 152). Germanys Excellence Strategy (CIBSS, EXC-2189, project ID 390939984) supported the work of C.H., A.K., and M.K.. S.P. was funded by H2020 MSCA-ITN-2019 ID:860977 (TrainCKDis). The work of P.S. was supported by DFG Project-ID 523737608 (SCHL 2292/2-1). Genotyping and urine metabolomics in the GCKD study were supported by Bayer Pharma. Plasma metabolomics has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement no. 115974. The JU receives support from the European Unions Horizon 2020 research and innovation program and the EFPIA and the JDRF. Any dissemination of results reflects only the authors view; the JU is not responsible for any use that may be made of the information it contains. The GCKD study was and is supported by the BMBF (FKZ 01ER 0804, 01ER 0818, 01ER 0819, 01ER 0820 and 01ER 0821) and the KfH Foundation for Preventive Medicine. Unregistered grants to support the study were provided by corporate sponsors (listed at https://gckd.org). We are grateful for the willingness of the patients to participate in the GCKD study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The GCKD study was registered in the national registry for clinical studies (DRKS 00003971) and approved by local ethic committees of the participating institutions (universities or medical faculties of Aachen, Berlin, Erlangen, Freiburg, Hannover, Heidelberg, Jena, München and Würzburg). All participants provided written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
